These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31460612)

  • 1. [Budget impact of the incorporation of second-line drug treatment for diabetic macular edema in the Brazilian Unified National Health System from the perspective of the Minas Gerais State Health Department, Brazil].
    Izidoro JB; Piazza T; Andrade EIG; Alvares-Teodoro J
    Cad Saude Publica; 2019 Aug; 35(8):e00145518. PubMed ID: 31460612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diabetic retinopathy clinical research network analysis of the cost-effectiveness of aflibercept, bevacizumab and ranibizumab for the treatment of diabetic macular oedema and its application in Spain.
    Navarro-Navarro A; Salom D; Martínez-Toldos JJ; Udaondo P; Fernández-Martínez C; Gutiérrez-Arias L; Hervás A; Rodrigo R
    Arch Soc Esp Oftalmol; 2017 May; 92(5):245-246. PubMed ID: 28215618
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
    Cai S; Bressler NM
    Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.
    Jampol LM; Glassman AR; Bressler NM
    JAMA Ophthalmol; 2015 Sep; 133(9):983-4. PubMed ID: 26087135
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective.
    Meunier A; Opeifa O; Longworth L; Cox O; Bührer C; Durand-Zaleski I; Kelly SP; Gale RP
    Eye (Lond); 2024 Jul; 38(10):1917-1925. PubMed ID: 38555401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
    Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
    Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic macular edema, innovative technologies and economic impact: New opportunities for the Lombardy Region healthcare system?
    Foglia E; Ferrario L; Bandello F; Ferri C; Figini I; Franzin M; Gambaro G; Introini U; Medaglia M; Staurenghi G; Tadini P; Fomiatti A; Croce D
    Acta Ophthalmol; 2018 Jun; 96(4):e468-e474. PubMed ID: 29240298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
    JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
    Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
    Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.
    Wood EH; Karth PA; Moshfeghi DM; Leng T
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):950-4. PubMed ID: 26469235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.
    Rahimy E; Shahlaee A; Khan MA; Ying GS; Maguire JI; Ho AC; Regillo CD; Hsu J
    Am J Ophthalmol; 2016 Apr; 164():118-27.e2. PubMed ID: 26748058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015.
    Hollingworth W; Jones T; Reeves BC; Peto T
    BMJ Open; 2017 Oct; 7(10):e018289. PubMed ID: 29061629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ziv-aflibercept in macular disease.
    Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
    Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacoeconomic analysis of anti-angiogenic drugs for diabetic macular edema].
    Krysanov IS; Klabukova DL; Krysanova VS; Ermakova VY
    Vestn Oftalmol; 2024; 140(2):112-120. PubMed ID: 38742507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
    Glassman AR; Liu D; Jampol LM; Sun JK;
    Invest Ophthalmol Vis Sci; 2018 Mar; 59(3):1199-1205. PubMed ID: 29625440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher priced drugs are not cost effective for diabetic macular edema, US study finds.
    McCarthy M
    BMJ; 2016 Jun; 353():i3253. PubMed ID: 27283845
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
    Hussain RM; Ciulla TA
    Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.